Uric Acid appears to be one of the most important prognostic markers and one of the principal risk factors for cardiovascular diseases. The aim of our study was to assess three groups of patients: a first group treated with Allopurinol (AL), a second group not adequately controlled by treatment with AL or allergic to AL switched to treatment with Febuxostat (AL/FB) and a third group of naive patients immediately treated with Febuxostat (FB). The effectiveness and tolerability of both drugs were therefore assessed over time.
Materials and methods: 44 patients, with CKD in conservative therapy, were divided into 3 groups. A group of 20 patients (AL) with well controlled uricemic values (serum uric acid < 6 mg/dl); a group of 12 patients (AL/FB) with not well controlled uricemic values (serum uric acid concentration > 6.0 mg / dl) and / or intolerant to AL that were switched to treatment with FB, then a group of 12 naive patients (FB) treated immediately with FB. At time 0,3,6,9,12,18,24 months, all patients were monitored as regards: serum uric acid, renal function parameters, serum electrolytes, hemoglobin, lipid profile, blood glucose, glycated hemoglobin, proteinuria 24 hours,parathyroid hormone (PTH), C Reactive Protein (CRP). The doses of anti-uric acid administered drug were also evaluated. All the patients underwent a monitoring of blood pressure (BP), heart rate (HR) and body mass index (BMI).
Keywords:
Published on: Jun 19, 2017 Pages: 30-33
Full Text PDF
Full Text HTML
DOI: 10.17352/2455-5495.000023
CrossMark
Publons
Harvard Library HOLLIS
Search IT
Semantic Scholar
Get Citation
Base Search
Scilit
OAI-PMH
ResearchGate
Academic Microsoft
GrowKudos
Universite de Paris
UW Libraries
SJSU King Library
SJSU King Library
NUS Library
McGill
DET KGL BIBLiOTEK
JCU Discovery
Universidad De Lima
WorldCat
VU on WorldCat
PTZ: We're glad you're here. Please click "create a new query" if you are a new visitor to our website and need further information from us.
If you are already a member of our network and need to keep track of any developments regarding a question you have already submitted, click "take me to my Query."